Batoclimab, a new antibody aimed at the IL-15 target, is gaining attention as a encouraging clinical option for individuals diagnosed with difficult-to-treat ulcerative colitis who have responded adequately to existing medications. Early clinical trials suggest that batoclimab can considerably al